Literature DB >> 24353335

Predicting dementia in Parkinson disease by combining neurophysiologic and cognitive markers.

Kim T E Olde Dubbelink1, Arjan Hillebrand, Jos W R Twisk, Jan Berend Deijen, Diederick Stoffers, Ben A Schmand, Cornelis J Stam, Henk W Berendse.   

Abstract

OBJECTIVE: To assess the ability of neurophysiologic markers in conjunction with cognitive assessment to improve prediction of progression to dementia in Parkinson disease (PD).
METHODS: Baseline cognitive assessments and magnetoencephalographic recordings from 63 prospectively included PD patients without dementia were analyzed in relation to PD-related dementia (PDD) conversion over a 7-year period. We computed Cox proportional hazard models to assess the risk of converting to dementia conveyed by cognitive and neurophysiologic markers in individual as well as combined risk factor analyses.
RESULTS: Nineteen patients (30.2%) developed dementia. Baseline cognitive performance and neurophysiologic markers each individually predicted conversion to PDD. Of the cognitive test battery, performance on a posterior (pattern recognition memory score < median; hazard ratio (HR) 6.80; p = 0.001) and a fronto-executive (spatial span score < median; HR 4.41; p = 0.006) task most strongly predicted dementia conversion. Of the neurophysiologic markers, beta power < median was the strongest PDD predictor (HR 5.21; p = 0.004), followed by peak frequency < median (HR 3.97; p = 0.016) and theta power > median (HR 2.82; p = 0.037). In combination, baseline cognitive performance and neurophysiologic measures had even stronger predictive value, with the combination of impaired fronto-executive task performance and low beta power being associated with the highest dementia risk (both risk factors vs none: HR 27.3; p < 0.001).
CONCLUSIONS: Combining neurophysiologic markers with cognitive assessment can substantially improve dementia risk profiling in PD, providing potential benefits for clinical care as well as for the future development of therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24353335     DOI: 10.1212/WNL.0000000000000034

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  28 in total

Review 1.  What can biomarkers tell us about cognition in Parkinson's disease?

Authors:  Brit Mollenhauer; Lynn Rochester; Alice Chen-Plotkin; David Brooks
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

2.  Brain (18)F-DOPA PET and cognition in de novo Parkinson's disease.

Authors:  Agnese Picco; Silvia Morbelli; Arnoldo Piccardo; Dario Arnaldi; Nicola Girtler; Andrea Brugnolo; Irene Bossert; Lucio Marinelli; Antonio Castaldi; Fabrizio De Carli; Claudio Campus; Giovanni Abbruzzese; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-28       Impact factor: 9.236

Review 3.  A clinicopathological approach to the diagnosis of dementia.

Authors:  Fanny M Elahi; Bruce L Miller
Journal:  Nat Rev Neurol       Date:  2017-07-14       Impact factor: 42.937

Review 4.  The Neuropsychiatry of Parkinson Disease: A Perfect Storm.

Authors:  Daniel Weintraub; Eugenia Mamikonyan
Journal:  Am J Geriatr Psychiatry       Date:  2019-03-09       Impact factor: 4.105

5.  Profiling Parkinson's disease cognitive phenotypes via resting-state magnetoencephalography.

Authors:  Olivier B Simon; Donald C Rojas; Debashis Ghosh; Xinyi Yang; Sarah E Rogers; Christine S Martin; Samantha K Holden; Benzi M Kluger; Isabelle Buard
Journal:  J Neurophysiol       Date:  2021-12-22       Impact factor: 2.714

Review 6.  Lewy body dementias.

Authors:  Zuzana Walker; Katherine L Possin; Bradley F Boeve; Dag Aarsland
Journal:  Lancet       Date:  2015-10-24       Impact factor: 79.321

Review 7.  Neuroimaging of Parkinson's disease: Expanding views.

Authors:  Carol P Weingarten; Mark H Sundman; Patrick Hickey; Nan-kuei Chen
Journal:  Neurosci Biobehav Rev       Date:  2015-09-26       Impact factor: 8.989

8.  Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease.

Authors:  Brenna Cholerton; Catherine O Johnson; Brian Fish; Joseph F Quinn; Kathryn A Chung; Amie L Peterson-Hiller; Liana S Rosenthal; Ted M Dawson; Marilyn S Albert; Shu-Ching Hu; Ignacio F Mata; James B Leverenz; Kathleen L Poston; Thomas J Montine; Cyrus P Zabetian; Karen L Edwards
Journal:  Parkinsonism Relat Disord       Date:  2018-02-09       Impact factor: 4.891

9.  EEG spectral power abnormalities and their relationship with cognitive dysfunction in patients with Alzheimer's disease and type 2 diabetes.

Authors:  Christopher S Y Benwell; Paula Davila-Pérez; Peter J Fried; Richard N Jones; Thomas G Travison; Emiliano Santarnecchi; Alvaro Pascual-Leone; Mouhsin M Shafi
Journal:  Neurobiol Aging       Date:  2019-10-14       Impact factor: 4.673

10.  MEGnet: Automatic ICA-based artifact removal for MEG using spatiotemporal convolutional neural networks.

Authors:  Alex H Treacher; Prabhat Garg; Elizabeth Davenport; Ryan Godwin; Amy Proskovec; Leonardo Guimaraes Bezerra; Gowtham Murugesan; Ben Wagner; Christopher T Whitlow; Joel D Stitzel; Joseph A Maldjian; Albert A Montillo
Journal:  Neuroimage       Date:  2021-07-16       Impact factor: 7.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.